Abstract
Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of EWSR1/FUS::TFCP2 and MEIS1::NCOA2. The former often follow an aggressive clinical course; there is limited clinical follow-up available for the latter. We report here a new case of the very rare intraosseous SSRMS with MEIS1::NCOA2 gene fusion and include the detailed treatment course and 52 months of clinical follow-up. SSRMS with MEIS1::NCOA2 gene fusion appears biologically distinct from other intraosseous SSRMS, following a course characterized by local recurrence with rare reports of metastasis to date.
Original language | English (US) |
---|---|
Pages (from-to) | 704-712 |
Number of pages | 9 |
Journal | Cancer Investigation |
Volume | 41 |
Issue number | 8 |
DOIs | |
State | Published - 2023 |
Keywords
- MEIS1
- NCOA2
- Rhabdomyosarcoma
- bone
- gene fusion
ASJC Scopus subject areas
- Oncology
- Cancer Research